Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Heterobivalent dual-target probe for targeting GRP and Y1 receptors on tumor cells.

Shrivastava A, Wang SH, Raju N, Gierach I, Ding H, Tweedle MF.

Bioorg Med Chem Lett. 2013 Feb 1;23(3):687-92. doi: 10.1016/j.bmcl.2012.11.110. Epub 2012 Dec 5.

2.
3.

(18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer.

Liu Z, Yan Y, Liu S, Wang F, Chen X.

Bioconjug Chem. 2009 May 20;20(5):1016-25. doi: 10.1021/bc9000245.

4.

Evaluation of 64Cu-labeled bifunctional chelate-bombesin conjugates.

Ait-Mohand S, Fournier P, Dumulon-Perreault V, Kiefer GE, Jurek P, Ferreira CL, Bénard F, Guérin B.

Bioconjug Chem. 2011 Aug 17;22(8):1729-35. doi: 10.1021/bc2002665. Epub 2011 Jul 29.

PMID:
21761921
5.

Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer.

Richter S, Wuest M, Krieger SS, Rogers BE, Friebe M, Bergmann R, Wuest F.

Nucl Med Biol. 2013 Nov;40(8):1025-34. doi: 10.1016/j.nucmedbio.2013.07.005. Epub 2013 Aug 19.

PMID:
23969085
6.

Investigation of bombesin peptide as a targeting ligand for the gastrin releasing peptide (GRP) receptor.

Begum AA, Moyle PM, Toth I.

Bioorg Med Chem. 2016 Nov 15;24(22):5834-5841. doi: 10.1016/j.bmc.2016.09.039. Epub 2016 Sep 16.

PMID:
27670095
7.

In vitro and in vivo evaluation of Alexa Fluor 680-bombesin[7-14]NH2 peptide conjugate, a high-affinity fluorescent probe with high selectivity for the gastrin-releasing peptide receptor.

Ma L, Yu P, Veerendra B, Rold TL, Retzloff L, Prasanphanich A, Sieckman G, Hoffman TJ, Volkert WA, Smith CJ.

Mol Imaging. 2007 May-Jun;6(3):171-80.

PMID:
17532883
8.

64Cu-NO2A-RGD-Glu-6-Ahx-BBN(7-14)NH2: a heterodimeric targeting vector for positron emission tomography imaging of prostate cancer.

Jackson AB, Nanda PK, Rold TL, Sieckman GL, Szczodroski AF, Hoffman TJ, Chen X, Smith CJ.

Nucl Med Biol. 2012 Apr;39(3):377-87. doi: 10.1016/j.nucmedbio.2011.10.004. Epub 2012 Jan 5.

9.

[64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues.

Prasanphanich AF, Nanda PK, Rold TL, Ma L, Lewis MR, Garrison JC, Hoffman TJ, Sieckman GL, Figueroa SD, Smith CJ.

Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12462-7. Epub 2007 Jul 12.

10.

A human GRPr-transfected Ace-1 canine prostate cancer model in mice.

Ding H, Kothandaraman S, Gong L, Williams MM, Dirksen WP, Rosol TJ, Tweedle MF.

Prostate. 2016 Jun;76(9):783-95. doi: 10.1002/pros.23172. Epub 2016 Mar 4.

PMID:
26940014
11.

A high-affinity near-infrared fluorescent probe to target bombesin receptors.

Shrivastava A, Ding H, Kothandaraman S, Wang SH, Gong L, Williams M, Milum K, Zhang S, Tweedle MF.

Mol Imaging Biol. 2014 Oct;16(5):661-9. doi: 10.1007/s11307-014-0727-2.

PMID:
24604209
12.

(68)Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging.

Liu Z, Niu G, Wang F, Chen X.

Eur J Nucl Med Mol Imaging. 2009 Sep;36(9):1483-94. doi: 10.1007/s00259-009-1123-z. Epub 2009 Apr 10.

PMID:
19360404
13.

A new (68)Ga-labeled BBN peptide with a hydrophilic linker for GRPR-targeted tumor imaging.

Pan D, Xu YP, Yang RH, Wang L, Chen F, Luo S, Yang M, Yan Y.

Amino Acids. 2014 Jun;46(6):1481-9. doi: 10.1007/s00726-014-1718-y. Epub 2014 Mar 17.

PMID:
24633452
14.

[Lys(DOTA)4]BVD15, a novel and potent neuropeptide Y analog designed for Y1 receptor-targeted breast tumor imaging.

Guérin B, Dumulon-Perreault V, Tremblay MC, Ait-Mohand S, Fournier P, Dubuc C, Authier S, Bénard F.

Bioorg Med Chem Lett. 2010 Feb 1;20(3):950-3. doi: 10.1016/j.bmcl.2009.12.068. Epub 2009 Dec 23.

PMID:
20042335
15.

Radiochemical investigations of 177Lu-DOTA-8-Aoc-BBN[7-14]NH2: an in vitro/in vivo assessment of the targeting ability of this new radiopharmaceutical for PC-3 human prostate cancer cells.

Smith CJ, Gali H, Sieckman GL, Hayes DL, Owen NK, Mazuru DG, Volkert WA, Hoffman TJ.

Nucl Med Biol. 2003 Feb;30(2):101-9.

PMID:
12623108
16.

In vitro and in vivo analysis of [(64)Cu-NO2A-8-Aoc-BBN(7-14)NH(2)]: a site-directed radiopharmaceutical for positron-emission tomography imaging of T-47D human breast cancer tumors.

Prasanphanich AF, Retzloff L, Lane SR, Nanda PK, Sieckman GL, Rold TL, Ma L, Figueroa SD, Sublett SV, Hoffman TJ, Smith CJ.

Nucl Med Biol. 2009 Feb;36(2):171-81. doi: 10.1016/j.nucmedbio.2008.11.005.

17.

Radiochemical investigations of [188Re(H2O)(CO)3-diaminopropionic acid-SSS-bombesin(7-14)NH2]: syntheses, radiolabeling and in vitro/in vivo GRP receptor targeting studies.

Smith CJ, Sieckman GL, Owen NK, Hayes DL, Mazuru DG, Volkert WA, Hoffman TJ.

Anticancer Res. 2003 Jan-Feb;23(1A):63-70.

PMID:
12680195
18.

Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma.

Yang YS, Zhang X, Xiong Z, Chen X.

Nucl Med Biol. 2006 Apr;33(3):371-80. Epub 2006 Mar 9.

PMID:
16631086
19.

microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.

Chen X, Park R, Hou Y, Tohme M, Shahinian AH, Bading JR, Conti PS.

J Nucl Med. 2004 Aug;45(8):1390-7.

20.

In vitro binding evaluation of 177Lu-AMBA, a novel 177Lu-labeled GRP-R agonist for systemic radiotherapy in human tissues.

Thomas R, Chen J, Roudier MM, Vessella RL, Lantry LE, Nunn AD.

Clin Exp Metastasis. 2009;26(2):105-19. doi: 10.1007/s10585-008-9220-0. Epub 2008 Oct 31.

PMID:
18975117

Supplemental Content

Support Center